Recovery time.

In a truly non-US research effort, the UK enrolled—since March alone—11,500 patients across 175 NHS hospitals onto its randomized RECOVER trial evaluating the use of 6 mg oral dexamethasone daily x 10 days for the treatment of COVID-19. In a globally-anticipated press release, the trialists report outcomes among the first evaluable 6425 patients demonstrating a significant reduction in death with the addition of dex among patients requiring supplemental oxygen (HR 0.80) and ventilation (HR 0.65). | University of Oxford 2020